v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 30, 2024
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]      
Net income $ 7,265,396 $ 5,358,217 $ 3,827,772
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 441,533 386,277 359,699
Deferred income taxes (289,062) (363,247) (198,981)
Equity-based compensation expense 386,381 343,371 293,058
Other, net (32,712) 6,845 10,243
Changes in operating asset and liability accounts:      
Accounts receivable, net of allowance (1,962,108) (858,748) 303,443
Inventories (93,860) (180,733) 528,723
Prepaid expenses and other assets 50,240 (206,729) (15,535)
Trade accounts payable 417,507 212,000 125,939
Deferred profit (286,372) 1,147,759 (277,440)
Accrued expenses and other liabilities (39,286) 328,252 (304,652)
Net cash provided by operating activities 5,857,657 6,173,264 4,652,269
CASH FLOWS FROM INVESTING ACTIVITIES:      
Capital expenditures and intangible assets (966,405) (759,186) (396,670)
Proceeds from maturities of available-for-sale securities 0 0 34,336
Proceeds from sales of available-for-sale securities 0 0 3,430
Other, net 44,253 51,094 (11,710)
Net cash used for investing activities (922,152) (708,092) (370,614)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Principal payments on long-term debt and finance lease obligations and payments for debt issuance costs (755,428) (507,488) (256,104)
Treasury stock purchases (3,851,343) (3,422,321) (2,842,807)
Dividends paid (1,270,635) (1,149,542) (1,018,915)
Reissuances of treasury stock related to employee stock purchase plan 155,965 140,113 119,966
Proceeds from issuance of common stock 17,447 2,452 15,553
Other, net (13,793) 143 (13,543)
Net cash used for financing activities (5,717,787) (4,936,643) (3,995,850)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (27,431) 28,324 (22,374)
Net change in cash, cash equivalents and restricted cash (809,713) 556,853 263,431
Cash, cash equivalents and restricted cash at beginning of year [1] 6,407,656 5,850,803 5,587,372
Cash, cash equivalents and restricted cash at end of year [1] 5,597,943 6,407,656 5,850,803
Schedule of non-cash transactions      
Accrued payables for stock repurchases, including applicable excise tax 34,348 38,525 51,471
Accrued payables for capital expenditures 119,605 80,799 60,826
Dividends payable 325,402 291,981 260,905
Transfers of finished goods inventory to property and equipment 125,691 90,873 71,267
Supplemental disclosures:      
Cash payments for interest 150,101 172,355 173,094
Reconciliation of cash, cash equivalents, and restricted cash      
Cash and cash equivalents 5,579,171 6,390,659 5,847,856
Restricted cash and cash equivalents [1] 18,772 16,997 2,947
Total cash, cash equivalents, and restricted cash [1] $ 5,597,943 $ 6,407,656 $ 5,850,803
[1] Restricted cash is reported within Other assets in the Consolidated Balance Sheets